The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine

AIDS

Volumn 14, Issue 4, 2000, Pages 405-413

  Gisolf, Elisabeth H ^a,b   Jurriaans, Suzanne ^b   Pelgrom, Jolanda ^c   Van Wanzeele, Filip ^f   Van der Ende, Marchina E ^f   Brinkman, Kees ^f   Borst, Marie José ^f   De Wolf, Frank ^b   Japour, Anthony J ^d   Danner, Sven A ^a,e  

^a Natl AIDS Therapy Evaluation Centre   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d ABBOTT LABORATORIES   (United States)

^e Division of Infectious Diseases   (Netherlands)

^f NONE

Author keywords

HIV; Protease inhibitors; Stavudine; Treatment intensification

Indexed keywords

HYDROXYUREA; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TINGLING; STATISTICS;

ADULT; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; STAVUDINE; VIRAL LOAD;

EID: 0034077203     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00014     Document Type: Article

References (16)

1. 1. Cameron B, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
2. 2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4+ cell counts of 200/mm3 or less. N Eng J Med 1997, 337:725-733.
3. 3. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
4. 4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
5. 5. Havlir DV, Marschner IC, Hirsch M, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple drug therapy. N Engl J Med 1998, 339:1261-1268.
6. 6. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients. N Engl J Med 1998, 339:1269-1276.
7. 7. Reijers M, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-190.
8. 8. Kempf D, Marsh K, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997, 41:654-660.
9. 9. Hsu A, Granneman G, Cao G, et al. Pharmacokinetic interactions between two HIV-protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
10. 10. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
11. 11. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999, 13:213-224.
12. 12. ACTG criteria, division of AIDS. Table for grading severity of adult adverse experiences. August 1992.
13. 13. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999, 13:797-804.
14. 14. Weverling GJ, Lange JMA, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-F122.
15. 15. Tashima K, Staszewski S, Stryker R, et al. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir, versus efavirenz + zidovudine + lamivudine, versus indinavir + zidovudine + lamivudine at 48 weeks. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract LB16].
16. 16. Nieuwkerk P, Gisolf EH, van Leeuwen R, Danner SA, Sprangers MAG. Impact of ritonavir/saquinavir versus ritonavir/saquinavir/ stavudine on patients' health-related quality of life: preliminary results. 12th World AIDS Conference. Geneva, June-July 1998. [abstract 14338].